drugset / Trial / NCT04784754

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04784754

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A pilot placebo-controlled randomized double-blind trial of Melatonin in outpatients with COVID-19 infection to evaluate Safety, Efficacy and Dose-ranging.

Timeline

Start
2021-04-01
Primary completion
2022-09-30
Completion
2022-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 3 mg Oral
Subject Melatonin Small molecule 30 mg Oral

Indications